Cite
HARVARD Citation
Shih, C. et al. (2021). TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1. Cancer letters. pp. 142-151. [Online].